Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer

[1]  P. Gibbs,et al.  Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Barni,et al.  Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies , 2012, Expert opinion on drug safety.

[3]  M. Ychou,et al.  Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors , 2012, Supportive Care in Cancer.

[4]  A. Ganti,et al.  Pulmonary toxicities from targeted therapies: a review , 2011, Targeted Oncology.

[5]  M. Lacouture,et al.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities , 2011, Supportive Care in Cancer.

[6]  B. Vincenzi,et al.  Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  E. Maiello,et al.  Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. , 2011, The oncologist.

[8]  A. Chan,et al.  How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? , 2011, Supportive Care in Cancer.

[9]  A. Tan,et al.  Meta-Analysis of Incidence and Risk of Hypomagnesemia with Cetuximab for Advanced Cancer , 2010, Chemotherapy.

[10]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Ximing J. Yang,et al.  Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients , 2010, Clinical Cancer Research.

[13]  Roger T. Anderson,et al.  Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life , 2010, Cancer.

[14]  D. Rigopoulos,et al.  Efficacy and safety of tacrolimus ointment 0·1% vs. betamethasone 17‐valerate 0·1% in the treatment of chronic paronychia: an unblinded randomized study. Reply from authors , 2010 .

[15]  M. Steinhoff,et al.  Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. , 2010, Journal of the American Academy of Dermatology.

[16]  T. Mesti,et al.  Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC). , 2010 .

[17]  J. Ocvirk,et al.  Management of cutaneous side‐effects of cetuximab therapy in patients with metastatic colorectal cancer , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  M. Aapro,et al.  Reduced incidence of infusion‐related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication , 2010, Cancer.

[19]  M. Lacouture,et al.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Saif,et al.  Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. , 2010, JOP : Journal of the pancreas.

[21]  M. Shah,et al.  Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience , 2010, Investigational New Drugs.

[22]  Lynne Wagner,et al.  A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group , 2010, Supportive Care in Cancer.

[23]  M. Zhu,et al.  Meta‐analysis: The efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer , 2009, Journal of digestive diseases.

[24]  E. Van Cutsem,et al.  Skin toxicities of targeted therapies. , 2009, European journal of cancer.

[25]  U. Rodeck,et al.  Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. , 2009, Cancer Research.

[26]  M. Giovannini,et al.  Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies , 2009, Journal of oncology.

[27]  J. Ocvirk,et al.  Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Lacouture,et al.  NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  A. Katsambas,et al.  Efficacy and safety of tacrolimus ointment 0·1% vs. betamethasone 17‐valerate 0·1% in the treatment of chronic paronychia: an unblinded randomized study , 2009, The British journal of dermatology.

[30]  S. Clarke,et al.  Cetuximab-associated pulmonary toxicity. , 2009, Clinical colorectal cancer.

[31]  E. Van Cutsem,et al.  Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy , 2009, Cancer.

[32]  M. Saif,et al.  Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature , 2009, Cancer Chemotherapy and Pharmacology.

[33]  K. Ang,et al.  Increased Oral Mucositis after IMRT versus Non-IMRT when Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234 , 2008 .

[34]  S. Misbah,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[35]  V. Adamo,et al.  Early Magnesium Reduction in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan as Predictive Factor of Efficacy and Outcome , 2008, Clinical Cancer Research.

[36]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[37]  P. Keegan,et al.  U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens , 2008, Clinical Cancer Research.

[38]  P. Ellis,et al.  Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  A. Raviv,et al.  Topical minocycline for managing symptoms of recurrent aphthous stomatitis. , 2008, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[40]  Rolf Hoffmann,et al.  A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% cream in the treatment of unwanted facial hair in women using TrichoScan. , 2008, European journal of dermatology : EJD.

[41]  M. Fakih.  Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. , 2008, Oncology.

[42]  A. Rademaker,et al.  Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results , 2007, Oncology.

[43]  A. Halpern,et al.  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Lebrun,et al.  3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC) , 2007 .

[45]  W. Zheng,et al.  The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. , 2007, The American journal of clinical nutrition.

[46]  Sabine Tejpar,et al.  Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. , 2007, The Journal of clinical investigation.

[47]  P. Novotny,et al.  Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB) , 2007 .

[48]  C. Köhne,et al.  Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial , 2007 .

[49]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Bingshu E. Chen,et al.  Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  E. Van Cutsem,et al.  Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. , 2007, The Lancet. Oncology.

[52]  M. Saif,et al.  Incidence and management of cutaneous toxicities associated with cetuximab , 2007, Expert opinion on drug safety.

[53]  A. Lavrijsen,et al.  Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. , 2007, European journal of cancer.

[54]  S. Yashar,et al.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. , 2007, Journal of the American Academy of Dermatology.

[55]  F. Ciardiello,et al.  Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST). , 2007 .

[56]  M. Lacouture,et al.  The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome , 2006, The British journal of dermatology.

[57]  M. Lacouture.  Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.

[58]  E. Roé,et al.  Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. , 2006, Journal of the American Academy of Dermatology.

[59]  G. Wilding,et al.  Cetuximab-induced hypomagnesemia in patients with colorectal cancer. , 2006, Clinical colorectal cancer.

[60]  J. Berlin,et al.  Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Pierce,et al.  AKT1 Provides an Essential Survival Signal Required for Differentiation and Stratification of Primary Human Keratinocytes* , 2006, Journal of Biological Chemistry.

[62]  M. Lacouture,et al.  Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab , 2006, The British journal of dermatology.

[63]  J. Raoul,et al.  Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment , 2006, Acta oncologica.

[64]  P. Pfeiffer,et al.  Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports. , 2006, Acta oncologica.

[65]  F. Ciardiello,et al.  Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment (Everest): Preliminary PK and efficacy data of a randomized study , 2006 .

[66]  E. Van Cutsem,et al.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  L. Saltz,et al.  Cetuximab therapy and symptomatic hypomagnesemia. , 2005, Journal of the National Cancer Institute.

[68]  R. Perez-soler,et al.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Alain Spatz,et al.  Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.

[70]  A. Halpern,et al.  HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.

[71]  G. Girolomoni,et al.  ERK1/2 Regulates Epidermal Chemokine Expression and Skin Inflammation1 , 2005, The Journal of Immunology.

[72]  C. Woodworth,et al.  Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment , 2005, Molecular Cancer Therapeutics.

[73]  C. Iacobuzio-Donahue,et al.  Genotypic bases of EGFR inhibitors pharmacological actions , 2004 .

[74]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  T. Gudermann,et al.  Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Lachapelle,et al.  [Acneiform eruptions induced by cetuximab]. , 2003, Annales de dermatologie et de venereologie.

[77]  D. Merenstein,et al.  Topical steroids more effective than antifungals for chronic paronychia. , 2002, The Journal of family practice.

[78]  E. Haddad,et al.  Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family , 2002, Nature Genetics.

[79]  A. Halpern,et al.  Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.

[80]  U. Wollina.  Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[81]  J. Hackney,et al.  STAT3 activation accompanies keratinocyte differentiation. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[82]  M. Pittelkow,et al.  EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. , 1997, The Journal of investigative dermatology.

[83]  W. Rutala,et al.  Uses of inorganic hypochlorite (bleach) in health-care facilities , 1997, Clinical microbiology reviews.

[84]  C. R. Daniel,et al.  Chronic paronychia and onycholysis: a thirteen-year experience. , 1996, Cutis.

[85]  R. Derynck,et al.  Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.

[86]  A. Pérez Pérez,et al.  Hypomagnesemic hypocalcemia in chronic renal failure. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[87]  Richardson,et al.  Terbinafine in chronic paronychia and candida onychomycosis , 1992 .

[88]  R. Siegel,et al.  Combined median and ulnar nerve lesions complicating fractures of the distal radius and ulna. Two case reports. , 1968 .